WO2008076143A1 - Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux - Google Patents

Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux Download PDF

Info

Publication number
WO2008076143A1
WO2008076143A1 PCT/US2007/009178 US2007009178W WO2008076143A1 WO 2008076143 A1 WO2008076143 A1 WO 2008076143A1 US 2007009178 W US2007009178 W US 2007009178W WO 2008076143 A1 WO2008076143 A1 WO 2008076143A1
Authority
WO
WIPO (PCT)
Prior art keywords
ylamine
amino
pyrimidin
imidazo
ylquinolin
Prior art date
Application number
PCT/US2007/009178
Other languages
English (en)
Inventor
Lee D. Arnold
Qun-Sheng Ji
Mark Joseph Mulvihill
Original Assignee
Osi Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/048222 external-priority patent/WO2007075554A2/fr
Application filed by Osi Pharmaceuticals, Inc. filed Critical Osi Pharmaceuticals, Inc.
Publication of WO2008076143A1 publication Critical patent/WO2008076143A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the present invention is directed to compositions and methods for treating cancer patients.
  • the present invention is directed to compositions and combined treatment of patients with novel substituted heterobicyclic IGFlR protein kinase inhibitors and anti-cancer agents.
  • Cancer is a generic name for a wide range of cellular malignancies characterized by unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize. These neoplastic malignancies affect, with various degrees of prevalence, every tissue and organ in the body.
  • a multitude of therapeutic agents have been developed over the past few decades for the treatment of various types of cancer.
  • anticancer agents include: DNA- alkylating agents (e.g., cyclophosphamide, ifosfamide), anti-metabolites (e.g., methotrexate, a folate antagonist, and 5-fluorouracil, a pyrimidine antagonist), microtubule disrupters (e.g., vincristine, vinblastine, paclitaxel), DNA intercalators (e.g., doxorubicin, daunomycin, cisplatin), and hormone therapy (e.g., tamoxifen, flutamide).
  • DNA- alkylating agents e.g., cyclophosphamide, ifosfamide
  • anti-metabolites e.g., methotrexate, a folate antagonist, and 5-fluorouracil, a pyrimidine antagonist
  • microtubule disrupters e.g., vincristine, vinblastine, paclitaxel
  • DNA intercalators e.
  • Colorectal cancer is among the leading causes of cancer-related morbidity and mortality in the U.S. Treatment of this cancer depends largely on the size, location and stage of the tumor, whether the malignancy has spread to other parts of the body (metastasis), and on the patient's general state of health. Options include surgical removal of tumors for early stage localized disease, chemotherapy and radiotherapy. However, chemotherapy is currently the only treatment for metastatic disease. 5- fluorouracil is currently the most effective single-agent treatment for advanced colorectal cancer, with response rates of about 10 %. Additionally, new agents such as the topoisomerase I inhibitor irinotecan (CPTl 1), the platinum-based cytotoxic agent oxaliplatin (e.g.
  • ELOXATINTM EGFR kinase inhibitor
  • erlotinib [6,7-bis(2-methoxyethoxy)-4-quinazolin-4-yl]-(3-ethynylphenyl)arnine, e.g. erlotinib HCl, TARCEV ATM
  • TGF-alpha is frequently associated with many cancers, including breast, lung, colorectal and head and neck cancers (Salomon D.S., et al. (1995) Crit. Rev. Oncol. Hematol. 19: 183-232; Wells, A. (2000) Signal, 1 :4-1 1), and is believed to contribute to the malignant growth of these tumors.
  • a specific deletion-mutation in the EGFR gene has also been found to increase cellular tumorigenicity (Halatsch, M-E. et al. (2000) J. Neurosurg. 92:297-305; Archer, G.E. et al. (1999) CHn. Cancer Res. 5:2646-2652).
  • EGFR stimulated signaling pathways promote multiple processes that are potentially cancer-promoting, e.g. proliferation, angiogenesis, cell motility and invasion, decreased apoptosis and induction of drug resistance.
  • cancer-promoting e.g. proliferation, angiogenesis, cell motility and invasion
  • anti -tumor agents of compounds that directly inhibit the kinase activity of the EGFR, as well as antibodies that reduce EGFR kinase activity by blocking EGFR activation are areas of intense research effort (de Bono J.S. and Rowinsky, E.K. (2002) Trends in MoI. Medicine 8:S19-S26, Dancey, J and Sausville, E A (2003) Nature Rev. Drug Discovery 2:92-313).
  • EGFR kinase inhibitors can improve tumor cell or neoplasia killing when used in combination with certain other anti-cancer or chemotherapeutic agents or treatments (e g. Raben, D. et al. (2002) Semin. Oncol. 29:37-46; Herbst, R S et al. (2001) Expert Opin. Biol Ther. 1 719-732; Magne, N et al (2003) Chn Can Res 9 4735-4732, Magne, N. et al. (2002) British Journal of Cancer 86:819-827; Torrance, CJ. et al. (2000) Nature Med 6 1024-1028; Gupta, R A.
  • An anti-neoplastic drug would ideally kill cancer cells selectively, with a wide therapeutic index relative to its toxicity towards non-malignant cells It would also retain its efficacy against malignant cells, even after prolonged exposure to the drug.
  • none of the current chemotherapies possess such an ideal profile. Instead, most possess very narrow therapeutic indexes
  • cancerous cells exposed to slightly sub-lethal concentrations of a chemotherapeutic agent will very often develop resistance to such an agent, and quite often cross-resistance to several other antineoplastic agents as well.
  • Combination therapy is well known as a method that can result in greater efficacy and diminished side effects relative to the use of the therapeutically relevant dose of each agent alone
  • the efficacy of the drug combination is additive (the efficacy of the combination is approximately equal to the sum of the effects of each drug alone), but in other cases the effect is synergistic (the efficacy of the combination is greater than the sum of the effects of each drug given alone)
  • 5-FU and leucovorin oxaliplatm exhibits response rates of 25- 40% as first-line treatment for colorectal cancer (Raymond, E. et al (1998) Semm Oncol. 25(2 Suppl 5) 4-12).
  • the present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an anti-cancer agent and IGFlR inhibitor combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy, wherein the IGFlR inhibitor relates to compounds of Formula I:
  • the invention also encompasses a pharmaceutical composition that is comprised of an anti -cancer agent and IGFlR inhibitor combination with a pharmaceutically acceptable carrier wherein the IGFlR inhibitor relates to compounds of Formula I-
  • a preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erloitinib HCl (also known as TARCEV ATM)
  • FIG. 1 Activation of IGF-I R pathways protected cells from growth inhibition and apoptosis by TARCEV ATM, and Combination of IGF-IR inhibitor (Compound A: 3-(4-Aminomethyl- cyclohexyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a] pyrazin-8-ylamine) with TARCEV ATM enhanced ability to inhibit cell proliferation (A), induce apoptosis (B) and block signaling pathways (C) in NSCLC H292 cells.
  • IGF-IR inhibitor Compound A: 3-(4-Aminomethyl- cyclohexyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a] pyrazin-8-ylamine
  • TARCEV ATM enhanced ability to inhibit cell proliferation (A), induce apoptosis (B) and block signaling pathways (C) in NSCLC H292 cells.
  • Figure 2 Synergistic effect of IGF- IR inhibitors (Compound A 3-(4-Aminomethyl- cyclohexyl)-1-(2-p henyl-quinohn-7-yl)-imidazo[1,5-a] pyrazin-8-ylamine & Compound B: 3-(3-
  • Figure 4 Bliss independence model of IGF-IR inhibitor (Compound B 3-(3-Azetidin- l-ylmethyl-cyclobutyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylamine) in combination with TARCEVATM in NSCLC cells
  • Figure 6 Synergistic effect of TARCEVATM in combination with IGF-IR inhibitors on cell proliferation in GEO cells.
  • IGF-IR inhibitor Compound C: cis-3-[3-(4-Methyl-piperazin-l-yl)-cyclobutyl] 1 -(2 -phenyl -qumolm-
  • IGF-IR inhibitor Compound C: cis-3-[3-(4-Methyl-piperazin-l-yl)-cyclobutyl]1-(2-phenyl-quinolin-
  • IGF-IR inhibitor Compound C: cis-3-[3-(4-Methyl-piperazin-l-yl)-cyclobutyl]1-(2-phenyl-quinohn-
  • TARCEV ATM in NSCLC and colorectal cancer xenograft tumor models TARCEV ATM in NSCLC and colorectal cancer xenograft tumor models.
  • the present invention is directed to compositions and methods for treating cancer patients comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an epidermal growth factor receptor (EGFR) kinase inhibitor and a novel heterobicyclic IGFlR protein kinase inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy.
  • the present invention is also directed to compositions and combined treatment of patients with novel heterobicyclic IGFlR protein kinase inhibitors, their salts, and compositions comprising them and epidermal growth factor receptor (EGFR) kinase inhibitors, their salts, or compositions comprising them.
  • the invention further encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and IGFlR inhibitor combination with a pharmaceutically acceptable earner.
  • the present invention includes compositions and methods for treating cancer patients comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and an IGFlR inhibitor combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy, wherein the IGFlR inhibitor is a compound of Formula I.
  • Xi and X 2 are each independently N or — C-(E') aa ;
  • X 3 , X 4 , Xe, and X 7 are each independently N or C;
  • X 11 , X 12 , X 13 , X 14 , Xi 5 , and Xj 6 are each independently N, -C-(E u ) bb , or -N + -O-;
  • R 1 is absent, C(noalkyl, cycloC 3 . 10 alkyl, bicycloCs.ioalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterobicycloCs -10 alkyl, spiroalkyl, or heterospiroalkyl, any of which is optionally substituted by one or more independent G 1 ' substituents;
  • E 1 , E 11 , G 1 , and G 41 are each independently halo, -CF 3 , -OCF 3 , -OR 2 , -NR 2 R 3 (R 2a ) j ,,
  • E 1 , E" or G 1 optionally is -(W) n -(Y 1 ) m -R 4 ;
  • E 1 , E 11 , G 1 , or G 41 optionally independently is aryl-Co--i 10 kyl, aryl— C 2 .ioalkenyl, aryl-C 2 .] oalkynyl, hetaryl-C 0- i oalkyl, hetaryl-C 2 .
  • R 2 , R 2a , R 3 , R 3a , R 222 , R 222a , R 333 , R 333a , R 21 , R 2al , R 31 , R 3al , R 2221 , R 222al , R 3331 , and R 333al are each independently C o-10 alkyl, C 2 .ioalkenyl, C 2- , O alkynyl, C 1 . 10 alkoxyC 1 .]oalkyl, C 1 . 10 alkoxyC 2 .
  • R 2 and R 3 , or R 222 and R 333 , or R 2221 and R 3331 are optionally taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted by one or more independent G n " substituents and wherein said ring optionally includes one or more heteroatoms other than the nitrogen to which R 2 and R 3 , or R 222 and R 333 , or R 2221 and R 3331 are attached;
  • W 1 and Y 1 are each independently -O-, -NR 7 -, -S(O) j7 -, -CR 5 R 6 -, -N(C(O)OR 7 )-,
  • R s with R 6 are optionally taken together with the carbon atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with one or more independent R 69 substituents and wherein said ⁇ ng optionally includes one or more heteroatoms;
  • R 7 , R 7a , and R 8 are each independently acyl, Co. 10 alkyl, C 2 _i O alkenyl, aryl, heteroaryl, heterocyclyl or cycloC 3-10 alkyl, any of which is optionally substituted by one or more independent G 111 substituents;
  • R 4 is Co -10 alkyl, C 2 l oalkenyl, C 2 i O alkynyl, aryl, heteroaryl, cycloC 3-10 alkyl, heterocyclyl, cycloC 3 galkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G 41 substituents;
  • R 69 is aryl-Co.
  • R 77 , R 78 , R 87 , R 88 , R 778 , and R 888 are each independently Co. io alkyl. C 2 .
  • l oalkyl cycloC 3-8 alkenylC 1-10 alkyl, cycloC 3 8 alkylC 2- ,oalkenyl, cycloC 3-8 alkenylC 2-10 alkenyl, cycloC 3- 8 alkylC 2 .ioalkynyl, cycloC 3-8 alkenylC 2-10 alkynyl, heterocyclyl-Co -10 alkyl, heterocyclyl-C(.ioalkenyl, heterocyclyl-C 2-10 alkynyl, C 1-10 alkylcarbonyl, C 2 _ 10 alkenylcarbonyl, C 2 .
  • alkynylcarbonyl C(- l oalkoxycarbonyl, C 1 l oalkoxycarbonylC 1-10 alkyl, monoC(. ⁇ alkylaminocarbonyl, diC 1-6 alkylaminocarbonyl, mono(aryl)aminocarbonyl, di(aryl)aminocarbonyl, or
  • R 77 , R 78 , R 87 , R 88 , R 778 , and R 888 are each independently aryl-C ⁇ oalkyl, aryl-C 2 .
  • n, m, j l,j la,j2a,j4,j4a, j5a,j7, andj ⁇ are each independently 0, 1, or 2 and
  • aa and bb are each independently 0 or 1
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 3 is N; X 1 , X 2 , and X 5 are C-(E') aa ; X 4 , Xe, and X 7 are C; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a pharmaceutically acceptable salt thereof, wherein X 4 is N; X], X 2 , and X 5 are C— (E') aa ; and X 3 , X 6 , and X 7 are C; and the other va ⁇ ables are desc ⁇ bed as above for Formula I.
  • the IGFlR inhibitor is represented by Formula
  • the IGFlR inhibitor is represented by Formula
  • the IGFlR inhibitor is represented by Formula
  • the TGFlR inhibitor is represented by Formula
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein Xi and X 4 are N; X 2 and X 5 are C-(E') aa ; X 3 , X 6 , and X 7 are C; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 1 is N; X 5 is N-(E 1 ) ⁇ ; X 2 is C-(E 1 ) ⁇ ; )( 3 , X 4 , X 6 , and X 7 are C, and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by Formula
  • the IGFlR inhibitor is represented by Formula
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 and X 3 are N; X, and X 5 are C-(E 1 )( a , X 4 , X 6 , and X 7 are C; and the other variables are described as above for Formula I
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 and X 4 are N; Xi and X 5 are C-(E 1 ) aa ; X 3 , X 6 , and X 7 are C; and the other variables are desc ⁇ bed as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 is N; X 5 is N-(E 1 ) ⁇ , Xi is C-(E 1 ) resort,; X 3 , X 4 , X 6 , and X 7 are C, and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 and X 6 are N; X 1 and X 5 are C-(E') aa , X 3 , X 4 , and X 7 are C; and the other variables are desc ⁇ bed as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 and X 7 are N; Xi and X 5 are C-(E 1 ) aa , X 3 , X 4 , and X 6 are C; and the other variables are desc ⁇ bed as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 3 and X 4 are N, X,, X 2 , and X 5 are C-(E 1 ),,,,; X 6 and X 7 are C, R' is absent, and the other va ⁇ ables are descnbed as above for Formula I
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 3 and X 5 are N, Xi and X 2 are C-(E 1 ) aa ; X 4 , X 6 , and X 7 are C, and the other variables are described as above for Formula I [76]
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 4 and X 5 are N, Xi and X 2 are C-(E') aa , X 3 , X 6 , and X 7 are C, and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 4 and X 6 are N; X 1 , X 2 , and X 5 are C-(E') aa , X 3 and X 7 are C, R 1 is absent; and the other variables are described as above for Formula I
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 4 and X 7 are N, Xi, X 2 , and X 5 are C-(E') aa , X 3 and X 6 are C, R 1 is absent; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 5 and X 6 are N; Xi and X 2 are ⁇ (E 1 ) ⁇ , X 3 , X 4 , and X 7 are C, and the other variables are described as above for Formula I
  • the IGFlR inhibitor is represented by
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , X 3 , and X 4 are N, X, and X 5 are C-(E 1 ⁇ 3 , X 6 and X 7 are C, R 1 is absent; and the other variables are desc ⁇ bed as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , X 3 , and X 5 are N; X, is C-(E') aa ; X 4 , X 6 and X 7 are C, and the other vanables are described as above for Formula I
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 3 , X 4 , and X 5 are N; Xi and X 2 are C— (E') aa , X 6 and X 7 are C, R 1 is absent; and the other variables are desc ⁇ bed as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein Xi, X 3 , and X 4 are N, X 2 and X 5 are C-(E 1 ) ⁇ , X 6 and X 7 are C, R 1 is absent; and the other variables are desc ⁇ bed as above for Formula I.
  • the IGFlR inhibitor is represented by Formula I, or a salt thereof, wherein Xi, X 4 , and X 5 are N; X 2 is C-(E') aa ; X 3 , X 6 and X 7 are C, and the other variables are described as above for Formula I
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , X 4 , and X 5 are N, Xi is C-(E') aa ; X 3 , X 6 and X 7 are C, and the other variables are desc ⁇ bed as above for Formula I
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , Xs, and X 6 are N; X t is C-(E') aa ; X 3 , X 4 , and X 7 are C; and the other variables are described as above for Formula I.
  • the IGF IR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 4 , X 5 , and X 6 are N; Xi and X 2 are C-(E') aa ; X 3 and X 7 are C; R 1 is absent; and the other variables are described as above for Formula I.
  • the IGF IR inhibitor is represented by
  • Formula I or a salt thereof, wherein Xi, X 3 , and X 5 are N; X 2 is C— (E') aa ; X 4 , Xe and X 7 are C; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein Xi, X 4 , and X 6 are N; X 2 and X 5 are C— (E') aa ; X 3 and X 7 are C; R 1 is absent; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein Xi, X 5 , and X 7 are N; X 2 is C-(E') aa ; X 3 , X 4 , and X 6 are C; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein Xi, X 4 , and X 7 are N; X 2 and X 5 are C-(E 1 ),,;,; X 3 and X 6 are C; R 1 is absent; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , X 4 , and X 6 are N; Xi and X 5 are C-(E') aa ; X 3 and X 7 are C; R 1 is absent; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , X 4 , and X 7 are N; Xi and X 5 are C-(E 1 ) ⁇ ; X 3 and X 6 are C; R 1 is absent; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , X 5 , and X 7 are N; Xi is C-CE 1 ) ⁇ ; X 3 , X 4 , and X 6 are C; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein Xi, X 4 , X 5 , and X 6 are N; X 2 is C— (E') aa ; X 3 and X 7 are C; R 1 is absent; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , X 4 , X 5 , and X 6 are N; X] is C-(E') aa ; X 3 and X 7 are C; R 1 is absent; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein Xi, X 3 , X 4 , and X 5 are N; X 2 is C-(E') aa ; X 6 and X 7 are C; R 1 is absent; and the other variables are described as above for Formula I.
  • the IGFlR inhibitor is represented by
  • Formula I or a salt thereof, wherein X 2 , X 3 , X 4 , and X 5 are N, Xi is C-(E') aa , X 6 and X 7 are C; R 1 is absent; and the other variables are desc ⁇ bed as above for Formula I.
  • the IGFlR inhibitor is represented by
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xn, Xi 2 , and X M are N; X 13 , X) 5 , and X 16 are C-(E 11 V; and the other variables are as desc ⁇ bed in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xn, Xi 2 , and Xi 5 are N; Xi 3 , X t4 , and X, 6 are C-(E 11 V; and the other variables are as desc ⁇ bed in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xn, X 12 , and Xi 6 are N, X n , X 14 , and X, 5 are C-(E 1 ') bb ; and the other va ⁇ ables are as desc ⁇ bed in each of the above aspects [106]
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 11 , Xu, and X 14 are N; X 12 , X] 5 , and X 16 are C-(E") bb ; and the other va ⁇ ables are as described in each of the above aspects [107]
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 11 , X 13 , and X 15 are N, X 12
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 11 , X 13 , and X, 6 are N, X
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xn, Xi 4 , and X 15 are N, X12. Xi3j and X 16 are C-(E") bb ; and the other variables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 11 , Xi 4 , and X t6 are N, X12, Xn, and X 15 are C-(E 1 ') bb , and the other va ⁇ ables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 11 , X 15 , and X, 6 are N, Xi2, Xi3, and X M are C-(E 11 V, an d tne other variables are as described in each of the above aspects.
  • the IGF 1 R inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 2 , Xn, and X M are N; X ⁇ i, Xi 5 , and X, 6 are C-(E 1 ') bb ; and the other variables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xi 2 , Xn.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 2 , Xn, and X) 6 are N; X M , X
  • the IGF 1 R inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 2 , X 14 , and X 16 are N; X 11 , Xi 3 , and X, 5 are C— (E") bb ; and the other variables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 12 , Xi 5 , and X, 6 are N; X 1 I , Xi 3 , and X !4 are C-(E 1 ') bb ; and the other variables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 13 , X 14 , and X 15 are N; X 1 1 , X 12 , and X, 6 are C— (E n ) bb ; and the other variables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 13 , X 14 , and X 16 are N; Xn, X
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X t4 , X 15 , and X
  • the IGF 1 R inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 3 , X 15 , and X 16 are N; X n , Xi2, and X 14 are C-(E")b b ; and the other variables are as described in each of the above aspects.
  • the IGFl R inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X n and X 12 are N; X, 3 , X] 4 , Xi5, and X 16 are C— (E")bb; and the other variables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 11 and X 13 are N; X 12 , X 14 , Xi 5 , and X 16 are C— (E") bb ; and the other variables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X n and X
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xi i and X
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X n and X, 6 are N, Xi 2 , Xn, Xi 4 , and XiS are C-(E")bt» and the other va ⁇ ables are as described in each of the above aspects [127]
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X] 2 and X, 3 are N, Xn, Xi4, Xi5, and Xi 6 are C-(E") b b; and the other va ⁇ ables are as desc ⁇ bed in each of the above aspects [128]
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof
  • the IGF 1 R inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 2 and X, 6 are N, X n , Xi3, X
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xi 3 and X, 4 are N; X n , Xi2» Xi5, and Xi ⁇ are C-(E 11 )(b! ar
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 3 and X 15 are N; X, ,, Xi2, Xi4, and X] 6 are C-(E M ) b b; and the other va ⁇ ables are as desc ⁇ bed in each of the above aspects.
  • the IGFl R inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X i3 and X] 6 are N; X 1 1 , X, 2 , Xu, and XiS are C— (E") b b; and the other va ⁇ ables are as desc ⁇ bed in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 4 and Xi 5 are N; Xi ⁇ , Xi2. Xi3, and Xi6 are C-(E 11 )(b!
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 14 and X, 6 are N; X M , Xi 2 , Xi 3 , and X ⁇ s are C— (E ⁇ )b b ; and the other variables are as described in each of the above aspects [136]
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xi 5 and X 16 are N, X
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X] 1 is N; X] 2 , Xn, Xu, X15, and X, 6 are C-(E 1 l ⁇ b , and the other variables are as described in each of the above aspects.
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 2 is N; X n , X 13 , Xu, Xis, and X
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 4 is N; X n , X 12 , X 13 , Xi 5 , and Xi 6 are C-(E 1 1 ) ⁇ & ; and the other va ⁇ ables are as desc ⁇ bed in each of the above aspects [141]
  • the IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X
  • 5 is N
  • Xn, Xi 2 , Xi 3 , Xi 4 , and X 16 are C-(E 11 ) ⁇
  • the other vanables are as desc ⁇ bed in each of the above aspects [142]
  • IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X] 1 and X 16 are N, X, 2 , Xi 3 , Xi 4 , and
  • Xis are C-(E 11 ⁇ ; and the other va ⁇ ables are as desc ⁇ bed in each of the above aspects
  • IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X, 4 and Xi 6 are N; X 11 , Xi 2 , X n , and
  • X 15 are C— (E M )b b , and the other variables are as desc ⁇ bed in each of the above aspects.
  • IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein Xj 5 and X 16 are N; Xn, X 12 , Xj 3 , and
  • X 14 are C-(E n ) b b; and the other variables are as desc ⁇ bed in each of the above aspects
  • IGFlR inhibitor is represented by Formula I, or a pharmaceutically acceptable salt thereof, wherein X 11 is N; X) 2 , X n , X, 4 , X
  • the IGFlR inhibitors included in the present invention include any one of,
  • the IGFlR inhibitors of the present invention include any one of, wherein
  • IGFlR inhibitors to be used in accordance with the present invention include those desc ⁇ bed in U.S. Patent Application No 1 1/095/162 and include the following inhibitors or pharmaceutically acceptable salts thereof:
  • [432] 4-[4-Amino-3-(6-chloro-2-phenoxyquinolin-7-yl)-pyrazolo[3,4-d]pyrimidin-1-yl]- cyclohexanecarboxylic acid amide; [433] 4-[4-Amino-3-(8-fluoro-2-phenylquinolin-7-yl)-pyrazolo[3,4-d]pyrimidin-1-yl]- cyclohexanecarboxylic acid amide;
  • the present invention includes a pharmaceutical composition comprising an anti-cancer agent, a pharmaceutically acceptable carrier, and an IGFR inhibitor represented by Formula I
  • X, and X 2 are each independently N or -C-(E') aa ;
  • X 5 is N, -C-(E 1 )( a , or -N-(E') aa ;
  • X 3 , X 4 , X 6 , and X 7 are each independently N or C; [585] wherein at least one of X 3 , X 4 , X 5 , X 6 , and X 7 is independently N or -N-(E') aa ; [586] Q 1 is
  • Xn, Xi 2 , Xi 3 , Xi4, Xi 5 , and X, 6 are each independently N, -C-(E 1 ') réelle assign, or -N + -O-;
  • R 1 is absent, Co_ioalkyl, cycloC 3 _ 10 alkyl, bicycloC 5 . 10 alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterobicycloCs.malkyl, spiroalkyl, or heterospiroalkyl, any of which is optionally substituted by one or more independent G 11 substituents;
  • E 1 , E" , G 1 , and G 41 are each independently halo, -CF 3 , -OCF 3 , -OR 2 , -NR 2 R 3 (R 2a ) j , ,
  • E 1 , E" or G 1 optionally is -(W) n -(Y 1 ),,, ⁇ 4 ;
  • E 1 , E", G 1 , or G 41 optionally independently is aryl-Co_ 10 alkyl, aryl-C 2- , O alkenyl, aryl-C 2-10 alkynyl, hetaryl-C(noalkyl, hetaryl-C 2 .
  • R 2 , R 2a , R 3 , R 3a , R 222 , R 222a , R 333 , R 333a , R 21 , R 2al , R 31 , R 3al , R 2221 , R 222al , R 3331 , and R 333al are each independently Co -10 alkyl, C 2 i O alkenyl, C 2 , O alkynyl, C 1 10 alkoxyC 1 l oalkyl, C 1 , 0 alkoxyC 2 l oalkenyl, C 1 ., 0 alkoxyC 2 .ioalkynyl, C 1 ioalkylthioC 2 10 alkenyl, C 1-4 oalkylthioC 2- l oalkynyl, cycloC 3 8 alkyl, cycloC 3 8 alkenyl, cycloC 3 8 alkylC 1 10 alkyl, cycloC 3 8
  • R 2 and R 3 , or R 222 and R 333 , or R 2221 and R 3331 are optionally taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ⁇ ng is optionally substituted by one or more independent G 111 1 substituents and wherein said ⁇ ng optionally includes one or more heteroatoms other than the nitrogen to which R 2 and R 3 , or R 222 and R 333 , or R 222 ' and R 3331 are attached;
  • W 1 and Y 1 are each independently -O-, -NR 7 -, -S(O) j7 -, -CR 5 R 6 -, -N(C(O)OR 7 )-,
  • Io alkyl C 2 . 10 alkenyl, C 2 ., o alkynyl, C 1 . 10 alkoxyC 2 . 10 alkenyl, C
  • R s with R 6 are optionally taken together with the carbon atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with one or more independent R 69 substituents and wherein said ring optionally includes one or more heteroatoms;
  • R 7 , R 7a , and R 8 are each independently acyl, Co -10 alkyl, C 2 . 10 alkenyl, aryl, heteroaryl, heterocyclyl or cycloCs -10 alkyl, any of which is optionally substituted by one or more independent G 111 substituents;
  • R 4 is Co -10 alkyl, C 2 . 10 alkenyl, C 2 .ioalkynyl, aryl, heteroaryl, cycloC 3 .]oalkyl, heterocyclyl, cycloC 3 - g alkenyl, or heterocycloalkenyl, any of which is optionally substituted by one or more independent G 41 substituents;
  • R 69 is aryl-Co -10 alkyl, aryl-C 2- , O alkenyl, aryl-C 2 . ⁇ oalkynyl, hetaryl-Co.i oalkyl, hetaryI-C 2- i O alkenyl, hetaryl-C 2 .
  • 0f-NR 78 R 88 , R 78 and R 88 are optionally taken together with the nitrogen atom to which they are attached to form a 3-10 membered saturated or unsaturated ring, wherein said ring is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, C 1 ., 0 alkoxy, -SO 2 NR 778 R 888 , or -NR 778 R 888 substituents, and wherein said ring optionally includes one or more heteroatoms other than the nitrogen to which R 78 and R 88 are attached;
  • R 77 , R 78 , R 87 , R 88 , R 778 , and R 888 are each independently Co. io alkyl, C 2-l0 alkenyl, C 2 . l oalkynyl, C 1 .ioalkoxyC 1 .ioalkyl, C
  • i oalkoxycarbonyl C 1- , O alkoxy carbonylC ) . i o alkyl, monoC i . ⁇ alkylaminocarbonyl, mono(aryl)aminocarbonyl, di(aryl)aminocarbonyl, or any of which is optionally substituted with one or more independent halo, cyano, hydroxy, nitro, C 1-4 oalkoxy, -SO 2 N(Co- 4 alkyl)(Co.
  • R 77 , R 78 , R 87 , R 88 , R 778 , and R 888 are each independently aryl-C 0 . ⁇ oalkyl, aryl-C 2 . loalkenyl, aryl-C 2- i O alkynyl, he taryl-C 0 , oalkyl, hetaryl-C 2 .i O alkenyl, hetaryl-C 2 .]oalkynyl, di(C 1-6 alkyl)aminoC 1 .
  • n, m, j l, jla, j2a, j4, j4a, j5a, j7, andj8 are each independently 0, 1, or 2;
  • aa and bb are each independently 0 or 1.
  • the present invention includes a pharmaceutical composition comprising an anti-cancer agent, a pharmaceutically acceptable carrier, and an IGFR inhibitor represented by Formula I
  • Xi, X 2 , X 4 , X 6 , and X 7 are C;
  • X n , X 12 , X 13 , X 14 , and X 15 are C;
  • R 1 is cycloC 3- i oalkyl optionally substituted by one or more independent G 11 substituents; and the remainder of the substituents are as defined as above.
  • the present invention includes a pharmaceutical composition comprising an anti-cancer agent, a pharmaceutically acceptable carrier, and an IGFR inhibitor selected from the group consisting of: [622] 3-Cyclobutyl-1-(2-pyridin-2-ylquinolin-7-yl)-imidazo[1,5--i]pyrazin-8-ylamine; [623] S-Cyclobutyl-1-CI-thiophen-2-ylquinolin-7-yl)-imidazof ljS-alpyrazin- ⁇ -ylamine; [624] 3-Cyclobutyl-l -(2 -phenoxyquinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylarnine;

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé permettant de traiter des tumeurs ou des métastases tumorales chez un patient, le procédé consistant à administrer au patient, simultanément ou de manière séquentielle, une quantité thérapeutiquement efficace d'une combinaison d'un agent anticancéreux et d'un composé inhibiteur du récepteur du facteur de croissance de l'insuline (IGF-1R) répondant à la formule I, avec ou sans agents ou traitements supplémentaires, tels que d'autres médicaments ou une thérapie par rayonnement anticancéreux. L'invention porte également sur une composition pharmaceutique constituée d'une combinaison d'un agent anticancéreux et d'un composé inhibiteur de l'IGF-1R répondant à la formule I, dans un support pharmaceutiquement acceptable. L'inhibiteur de l'IGF-1R est représenté par la formule (I) : X1, X2, X3, X4, X5, X6, X7, R1, et Q1 étant tels qu'ils sont définis dans le présent document.
PCT/US2007/009178 2006-12-18 2007-04-13 Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux WO2008076143A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US2006/048222 2006-12-18
PCT/US2006/048222 WO2007075554A2 (fr) 2005-12-19 2006-12-18 Traitement combine avec une composition d’inhibiteur de proteine kinase heterobicyclique a noyau 6,6-bicyclique et d'agents anticancereux

Publications (1)

Publication Number Publication Date
WO2008076143A1 true WO2008076143A1 (fr) 2008-06-26

Family

ID=39536603

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009178 WO2008076143A1 (fr) 2006-12-18 2007-04-13 Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux

Country Status (1)

Country Link
WO (1) WO2008076143A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106168A1 (fr) * 2007-02-27 2008-09-04 Osi Pharmaceuticals, Inc. Association de dérivés d'imizazo [1, 5-] pyrazynile et d'un agent inhibiteur de la phosphorylation sur sérine d'irs1 dans le traitement du cancer
WO2010017163A1 (fr) * 2008-08-04 2010-02-11 Wyeth Combinaisons antinéoplasiques de 4-anilino-3-cyanoquinoléines et de capécitabine
US7820662B2 (en) 2004-04-02 2010-10-26 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8481733B2 (en) 2008-05-19 2013-07-09 OSI Pharmaceuticals, LLC Substituted imidazopyr- and imidazotri-azines
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US9139558B2 (en) 2007-10-17 2015-09-22 Wyeth Llc Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9511063B2 (en) 2008-06-17 2016-12-06 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
US10596162B2 (en) 2005-02-03 2020-03-24 Wyeth Llc Method for treating gefitinib resistant cancer
US10729672B2 (en) 2005-11-04 2020-08-04 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
WO2020188015A1 (fr) 2019-03-21 2020-09-24 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
WO2021089791A1 (fr) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092599A1 (fr) * 2001-05-14 2002-11-21 Novartis Ag Derives 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine
WO2004056830A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Derives de pyrrolopyrimidine
WO2005097800A1 (fr) * 2004-04-02 2005-10-20 Osi Pharmaceuticals, Inc. Inhibiteurs de la proteine kinase heterobicycliques a substitution de noyau bicyclique 6,6
WO2007075554A2 (fr) * 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Traitement combine avec une composition d’inhibiteur de proteine kinase heterobicyclique a noyau 6,6-bicyclique et d'agents anticancereux

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092599A1 (fr) * 2001-05-14 2002-11-21 Novartis Ag Derives 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine
WO2004056830A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Derives de pyrrolopyrimidine
WO2005097800A1 (fr) * 2004-04-02 2005-10-20 Osi Pharmaceuticals, Inc. Inhibiteurs de la proteine kinase heterobicycliques a substitution de noyau bicyclique 6,6
WO2007075554A2 (fr) * 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Traitement combine avec une composition d’inhibiteur de proteine kinase heterobicyclique a noyau 6,6-bicyclique et d'agents anticancereux

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"BEVACIZUMAB AND GEMCITABINE COMBINED WITH EITHER CETUXIMAB OR ERLOTINIB IN TREATING PATIENTS WITH ADVANCED PANCREATIC CANCER", INTERNET CITATION, 7 September 2004 (2004-09-07), XP002410261, Retrieved from the Internet <URL:http://www.clinicaltrials.gov/ct/gui/show/NCT00091026> [retrieved on 20061201] *
VALERIOTE F ET AL: "SYNERGISTIC INTERACTION OF ANTICANCER AGENTS: A CELLULAR PERSPECTIVE", CANCER CHEMOTHERAPY REPORTS, vol. 59, no. 5, September 1975 (1975-09-01), pages 895 - 900, XP009019750 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367826B2 (en) 2004-04-02 2013-02-05 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8735405B2 (en) 2004-04-02 2014-05-27 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7820662B2 (en) 2004-04-02 2010-10-26 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8101613B2 (en) 2004-04-02 2012-01-24 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US10596162B2 (en) 2005-02-03 2020-03-24 Wyeth Llc Method for treating gefitinib resistant cancer
US10603314B2 (en) 2005-02-03 2020-03-31 The General Hospital Corporation Method for treating gefitinib resistant cancer
US10729672B2 (en) 2005-11-04 2020-08-04 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2008106168A1 (fr) * 2007-02-27 2008-09-04 Osi Pharmaceuticals, Inc. Association de dérivés d'imizazo [1, 5-] pyrazynile et d'un agent inhibiteur de la phosphorylation sur sérine d'irs1 dans le traitement du cancer
US9630946B2 (en) 2007-10-17 2017-04-25 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9139558B2 (en) 2007-10-17 2015-09-22 Wyeth Llc Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US10035788B2 (en) 2007-10-17 2018-07-31 Wyeth Llc Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US8481733B2 (en) 2008-05-19 2013-07-09 OSI Pharmaceuticals, LLC Substituted imidazopyr- and imidazotri-azines
US10111868B2 (en) 2008-06-17 2018-10-30 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
US9511063B2 (en) 2008-06-17 2016-12-06 Wyeth Llc Antineoplastic combinations containing HKI-272 and vinorelbine
EP2326329B1 (fr) 2008-08-04 2017-01-11 Wyeth LLC Combinaisons antinéoplasiques de 4-anilino-3-cyanoquinoléines et de capécitabine
EP3175853A1 (fr) * 2008-08-04 2017-06-07 Wyeth LLC Combinaisons antinéoplasiques contenant du neratinib et de la capécitabine
CN105963313A (zh) * 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
US9265784B2 (en) 2008-08-04 2016-02-23 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN109464445A (zh) * 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
AU2009279771B2 (en) * 2008-08-04 2015-05-14 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010017163A1 (fr) * 2008-08-04 2010-02-11 Wyeth Combinaisons antinéoplasiques de 4-anilino-3-cyanoquinoléines et de capécitabine
WO2020188015A1 (fr) 2019-03-21 2020-09-24 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
WO2021089791A1 (fr) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Similar Documents

Publication Publication Date Title
EP1979002A2 (fr) Combinaison d&#39;un inhibiteur de l&#39;igfr et d&#39;un agent anticancéreux
WO2008076143A1 (fr) Combinaison d&#39;un inhibiteur de l&#39;igfr et d&#39;un agent anticancéreux
US8575164B2 (en) Combination cancer therapy
WO2009009016A1 (fr) Traitement anticancéreux en combinaison
US20050272688A1 (en) Combined treatment with gemcitabine and an epidermal growth factor receptor kinase inhibitor
US20050271747A1 (en) Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor
WO2006081985A1 (fr) Traitement combine par un derive de n4-(oxycarbonyl substitue)-5&#39;-desoxy-5-fluorocytidine et un inhibiteur de l&#39;activite kinase du recepteur du facteur de croissance epidermique
US20050272737A1 (en) Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor
EP2400985A2 (fr) Thérapie anti-cancer combinée
US20060084675A1 (en) Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor
US20050272738A1 (en) Combined treatment with oxaliplatin and an epidermal growth factor receptor kinase inhibitor
US20090136517A1 (en) Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
US20070286864A1 (en) Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
US20060134064A1 (en) Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
US20070099856A1 (en) Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
KR100851271B1 (ko) 이리노테칸 （ｃｐｔ-１１） 및 ｅｇｆｒ-억제제를 이용한치료
WO2007146226A2 (fr) Traitement combiné avec un inhibiteur d&#39;egfr kinase et un agent qui sensibilise les cellules tumorales aux effets des inhibiteurs d&#39;egfr kinases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07775403

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07775403

Country of ref document: EP

Kind code of ref document: A1